Authors
Managing Editor—Science, Research, and Education at Yale School of Medicine.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
4
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
5
